Caplin Point Laboratories has announced its financial results for the quarter and half-year ended September 30, 2026. The company reported a total revenue of ₹1,307.04 crore for H1 FY27, marking a 19.1% increase year-on-year. Profit After Tax (PAT) for H1 FY27 stood at ₹361.42 crore, a rise of 16.2% compared to the previous year. The company also highlighted significant growth in EBITDA and other key financial metrics.
Caplin Point Laboratories Announces Strong H1 FY27 Financial Performance
Caplin Point Laboratories Limited has reported robust financial results for the half-year ended September 30, 2026. The company’s total revenue reached ₹1,307.04 crore, demonstrating a substantial 19.1% increase compared to ₹1,097.77 crore in the same period last year. This growth underscores the company’s expanding market presence and product offerings.
Key Financial Highlights for H1 FY27
Consolidated Income Statement
The consolidated income statement for H1 FY27 reveals a strong performance across key metrics:
- Revenue from Operations: Increased by 18.8% to ₹1,240.20 crore (H1 FY26: ₹1,044.26 crore).
- Gross Profit: Rose by 18.4% to ₹756.33 crore (H1 FY26: ₹638.72 crore).
- EBITDA: Grew by 19.8% to ₹503.54 crore (H1 FY26: ₹420.44 crore).
- Profit Before Tax (PBT): Increased by 18.8% to ₹458.05 crore (H1 FY26: ₹385.46 crore).
- Profit After Tax (PAT): Saw a growth of 16.2%, reaching ₹361.42 crore (H1 FY26: ₹310.99 crore).
Quarterly Performance (Q2 FY27)
For the second quarter ended September 30, 2026, the company also reported positive growth:
- Total Revenue: Grew by 17.5% to ₹663.13 crore (Q2 FY26: ₹564.41 crore).
- PAT: Increased by 13.8% to ₹182.35 crore (Q2 FY26: ₹160.23 crore).
Other Financial Highlights
The company emphasized several other positive financial aspects:
- Gross Margin for H1 FY27 was 61.0%.
- EBITDA Margin for H1 FY27 stood at 38.5%.
- Basic Earnings Per Share (EPS) for H1 FY27 was ₹46.71, an increase of 15.5% from H1 FY26.
- Cash Flow from Operations was ₹205 crore in H1 FY27.
- Free Cash Reserves amounted to ₹1,534 crore as of September 30, 2026.
These results reflect a sustained growth trajectory for Caplin Point Laboratories, driven by strong performance across its core business segments.
Source: BSE
